BioCentury | Jan 8, 2019
Distillery Therapeutics

Cancer

...in other models of melanoma. Abbott Laboratories and AbbVie Inc. market the PPARα agonist TriLipix fenofibric acid...
...a PPARα agonist, for hypercholesterolemia and hypertriglyceridemia. Aralez Pharmaceuticals Inc. markets the PPARα agonist Fibricor fenofibric acid...
BioCentury | Jun 15, 2015
Company News

Sun Pharmaceutical, Tribute Pharmaceuticals deal

...Tribute purchased U.S. rights from Sun to Fibricor fenofibric acid and its related authorized generic. Sun receives...
BioCentury | Feb 3, 2014
Finance

Quick payday on single cell sale

...adalimumab were up 13% to $3B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...
BioCentury | Oct 28, 2013
Finance

Paying the iron price

...adalimumab were up 16% to $2.8B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...
BioCentury | Jul 29, 2013
Finance

Green shoots in autumn

...adalimumab were up 12% to $2.6B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...
BioCentury | Jul 15, 2013
Clinical News

Cholib fenofibrate/simvastatin regulatory update

...the corresponding dose of simvastatin monotherapy. In territories outside the U.S., Abbott already markets Trilipix fenofibric acid...
...patients with severe hypertriglyceridemia, primary hyperlipidemia or mixed dyslipidemia. AbbVie Inc. (NYSE:ABBV, Chicago, Ill.) markets Trilipix...
BioCentury | Jul 1, 2013
Product Development

POC for APOCIIIRx

...either fail completely or are inadequate." Brinton was an investigator for AbbVie Inc. 's Trilipix fenofibric acid...
BioCentury | Apr 29, 2013
Finance

Plenty supply; shrinking demand

...adalimumab were up 16% to $2.2B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...
BioCentury | Nov 5, 2012
Strategy

Racing to rebuild AZ

...in January 2011, AstraZeneca and partner Abbott Laboratories stopped development of dyslipidemia candidate Certriad rosuvastatin/ fenofibric acid...
BioCentury | Apr 2, 2012
Clinical News

FP 250: Phase I data

...single doses of FP 250 led to significantly higher systemic exposure and plasma concentrations of fenofibric acid...
Items per page:
1 - 10 of 48